Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 2
2016 1
2018 1
2019 4
2020 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Premature ovarian failure 9"
Page 1
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. Grundy SM, et al. Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10. Circulation. 2019. PMID: 30586774 Free PMC article.
Risk-enhancing factors include family history of premature ASCVD; persistently elevated LDL-C levels 160 mg/dL (4.1 mmol/L); metabolic syndrome; chronic kidney disease; history of preeclampsia or premature menopause (age <40 years); chronic inflammatory di …
Risk-enhancing factors include family history of premature ASCVD; persistently elevated LDL-C levels 160 mg/dL (4.1 mmol/L); metaboli …
Mediterranean diet and female reproductive health over lifespan: a systematic review and meta-analysis.
Yang J, Song Y, Gaskins AJ, Li LJ, Huang Z, Eriksson JG, Hu FB, Chong YS, Zhang C. Yang J, et al. Am J Obstet Gynecol. 2023 Dec;229(6):617-631. doi: 10.1016/j.ajog.2023.05.030. Epub 2023 Jul 26. Am J Obstet Gynecol. 2023. PMID: 37506751 Review.
Subgroup analyses were performed for several pregnancy outcomes according to timing of the interventions for randomized controlled trials and timing of the dietary assessment for observational studies. RESULTS: Thirty-two studies (9 randomized controlled trials, 22 prospec …
Subgroup analyses were performed for several pregnancy outcomes according to timing of the interventions for randomized controlled trials an …
Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis.
Khattak H, Malhas R, Craciunas L, Afifi Y, Amorim CA, Fishel S, Silber S, Gook D, Demeestere I, Bystrova O, Lisyanskaya A, Manikhas G, Lotz L, Dittrich R, Colmorn LB, Macklon KT, Hjorth IMD, Kristensen SG, Gallos I, Coomarasamy A. Khattak H, et al. Hum Reprod Update. 2022 May 2;28(3):400-416. doi: 10.1093/humupd/dmac003. Hum Reprod Update. 2022. PMID: 35199164 Free PMC article.
BACKGROUND: Ovarian tissue cryopreservation involves freezing and storing of surgically retrieved ovarian tissue in liquid or vapour nitrogen below -190C. ...The pooled rates were 37% (95% CI: 32-43%) for pregnancy, 28% (95% CI: 24-34%) for live birth and 37% (95% C …
BACKGROUND: Ovarian tissue cryopreservation involves freezing and storing of surgically retrieved ovarian tissue in liquid or …
Childhood adversity and accelerated reproductive events: a systematic review and meta-analysis.
Ding W, Xu Y, Kondracki AJ, Sun Y. Ding W, et al. Am J Obstet Gynecol. 2024 Mar;230(3):315-329.e31. doi: 10.1016/j.ajog.2023.10.005. Epub 2023 Oct 10. Am J Obstet Gynecol. 2024. PMID: 37820985
Moderation analysis and meta-regression were used to investigate heterogeneity. RESULTS: In total, 21 cohort studies, 9 cross-sectional studies, and 3 case-control studies were identified. ...Among the 7 groups based on different reproductive events, including early onset …
Moderation analysis and meta-regression were used to investigate heterogeneity. RESULTS: In total, 21 cohort studies, 9 cross-section …
Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis.
Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Janse F, et al. Hum Reprod Update. 2012 Jul;18(4):405-19. doi: 10.1093/humupd/dms013. Epub 2012 Apr 23. Hum Reprod Update. 2012. PMID: 22525963 Review.
BACKGROUND: Increasing age and post-menopausal status are associated with decreasing androgen concentrations in females. Women with premature loss of ovarian function, such as primary ovarian insufficiency (POI) or iatrogenic menopause may be at increa …
BACKGROUND: Increasing age and post-menopausal status are associated with decreasing androgen concentrations in females. Women with prema …
Long-term health consequences of central precocious/early puberty (CPP) and treatment with Gn-RH analogue: a short update.
Soliman AT, Alaaraj N, De Sanctis V, Hamed N, Alyafei F, Ahmed S. Soliman AT, et al. Acta Biomed. 2023 Dec 5;94(6):e2023222. doi: 10.23750/abm.v94i6.15316. Acta Biomed. 2023. PMID: 38054666 Free PMC article.
RESULTS: Upon reviewing and analyzing selected studies, the following key findings emerged: (a) treating CPP in girls before age 6-7 and in boys before age 9 improves FHt; (b) bone mineral density (BMD) decreases during GnRHa treatment but normalizes afterward, with no las …
RESULTS: Upon reviewing and analyzing selected studies, the following key findings emerged: (a) treating CPP in girls before age 6-7 and in …
Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
Elgindy E, Sibai H, Abdelghani A, Mostafa M. Elgindy E, et al. Obstet Gynecol. 2015 Jul;126(1):187-95. doi: 10.1097/AOG.0000000000000905. Obstet Gynecol. 2015. PMID: 26241272 Review.
OBJECTIVE: To estimate whether gonadotropin-releasing hormone (GnRH) analog administration during chemotherapy can protect against development of ovarian toxicity. DATA SOURCES: MEDLINE (1966 to present), EMBASE (1980 to present), Cochrane Central Register of Controlled Tr …
OBJECTIVE: To estimate whether gonadotropin-releasing hormone (GnRH) analog administration during chemotherapy can protect against developme …
Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis.
Soman M, Huang LC, Cai WH, Xu JB, Chen JY, He RK, Ruan HC, Xu XR, Qian ZD, Zhu XM. Soman M, et al. Menopause. 2019 Jan;26(1):78-93. doi: 10.1097/GME.0000000000001161. Menopause. 2019. PMID: 29994966 Free PMC article.
OBJECTIVE: This meta-analysis aims to investigate serum androgen profiles (testosterone, dehydroepiandrosterone sulfate, androstenedione, and sex hormone-binding globulin) in women with premature ovarian failure and to establish if there is evidence of dimini …
OBJECTIVE: This meta-analysis aims to investigate serum androgen profiles (testosterone, dehydroepiandrosterone sulfate, androstenedione, an …
Hormone therapy and clinical and surrogate cardiovascular endpoints in women with chronic kidney disease: a systematic review and meta-analysis.
Ramesh S, Mann MC, Holroyd-Leduc JM, Wilton SB, James MT, Seely EW, Ahmed SB. Ramesh S, et al. Menopause. 2016 Sep;23(9):1028-37. doi: 10.1097/GME.0000000000000657. Menopause. 2016. PMID: 27433866 Review.
OBJECTIVE: Women with chronic kidney disease (CKD) experience kidney dysfunction-mediated premature menopause. The role of postmenopausal hormone therapy (HT) in this population is unclear. ...
OBJECTIVE: Women with chronic kidney disease (CKD) experience kidney dysfunction-mediated premature menopause. The role of pos …
Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H, Xiao L, Li J, Cui L, Huang W. Chen H, et al. Cochrane Database Syst Rev. 2019 Mar 3;3(3):CD008018. doi: 10.1002/14651858.CD008018.pub3. Cochrane Database Syst Rev. 2019. PMID: 30827035 Free PMC article.
In the GnRH agonist group, 326 of 447 participants had menstruation recovery or maintenance (72.9%) in comparison to the control group, in which 276 of 422 participants had menstruation recovery or maintenance (65.4%) during a follow-up period longer than 12 months (RR 1.0 …
In the GnRH agonist group, 326 of 447 participants had menstruation recovery or maintenance (72.9%) in comparison to the control grou …
15 results